Press release
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61Full-year 2022 revenues of $19.3 billion; GAAP net
About this update from Moderna, Inc.
[{"type":"text","content":"Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key marketsCompany will file for regulatory approval for mRNA-1345, Moderna's investigational RSV vaccine for older adults, in the first half of 2023. mRNA-1345 was recently granted FDA Breakthrough Therapy DesignationmRNA-1010 Phase 3 flu vaccine interim efficacy analysis expected to be reviewed by an independent DSMB before the end of the first quartermRNA-4157, Moderna's investigational personalized cancer vaccine in combination with Keytruda®, was granted Breakthrough Therapy Designation; full data set to be shared at upcoming medical oncology meeting and in peer reviewed publicationCompany R&D investments planned to increase to $4.5 billion in 2023CAMBRIDGE, MA / ACCESSWIRE / February 23, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022.\"2022 was another impressive year for Moderna, with over $19 billion in revenue and significant clinical breakthroughs across our portfolio. We continue to provide our Omicron-targeting bivalent vaccines worldwide, with the latest real-world evidence highlighting the continued protection of our vaccines against hospitalization and death,\" said Stéphane Bancel, Chief Executive Officer of Moderna. \"Our infectious disease platform continues to progress with positive Phase 3 data in RSV for older adults. We are investing to scale Phase 3 manufacturing for personalized cancer vaccines so that we can run several Phase 3 studies simultaneously. With planned R&D investments of $4.5 billion for the year, I am excited about the new medicines we believe we will bring to patients in the coming few years.\"Moderna is also announcing that Juan Andres, currently President, Strategic Partnerships and Enterprise Expansion, will be retiring from the Company in May after more than six years.\"Juan has played a tremendous role since joining Moderna in 2017. Juan served as Chief Technical Operations ...